4.6 Review

Are vesicular neurotransmitter transporters potential treatment targets for temporal lobe epilepsy?

期刊

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fncel.2013.00139

关键词

vesicular neurotransmitter transporters; temporal lobe epilepsy; epileptogenesis; antiepileptic drugs; SLC17; SLC18; SLC32

资金

  1. agency for Innovation by Science and Technology [IWT/SB/101344]
  2. Fund for Scientific Research Flanders (FWO, Belgium) [G038412N]
  3. Queen Elisabeth Medical Foundation
  4. EU COST Action [CM1103]

向作者/读者索取更多资源

The vesicular neurotransmitter transporters (VNTs) are small proteins responsible for packing synaptic vesicles with neurotransmitters thereby determining the amount of neurotransmitter released per vesicle through fusion in both neurons and glial cells. Each transporter subtype was classically seen as a specific neuronal marker of the respective nerve cells containing that particular neurotransmitter or structurally related neurotransmitters. More recently, however, it has become apparent that common neurotransmitters can also act as co-transmitters, adding complexity to neurotransmitter release and suggesting intriguing roles for VNTs therein. We will first describe the current knowledge on vesicular glutamate transporters (VGLUT1/2/3), the vesicular excitatory amino acid transporter (VEAT), the vesicular nucleotide transporter (VNUT), vesicular monoamine transporters (VMAT1/2), the vesicular acetylcholine transporter (VAChT) and the vesicular.-aminobutyric acid (GABA) transporter (VGAT) in the brain. We will focus on evidence regarding transgenic mice with disruptions in VNTs in different models of seizures and epilepsy. We will also describe the known alterations and reorganizations in the expression levels of these VNTs in rodent models for temporal lobe epilepsy (TLE) and in human tissue resected for epilepsy surgery. Finally, we will discuss perspectives on opportunities and challenges for VNTs as targets for possible future epilepsy therapies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Neurosciences

Nicotine modulation of the lateral habenula/ventral tegmental area circuit dynamics: An electrophysiological study in rats

Massimo Pierucci, Francis Delicata, Roberto Colangeli, Antonella Marino Gammazza, Alessandro Pitruzzella, Maurizio Casarrubea, Philippe De Deurwaerdere, Giuseppe Di Giovanni

Summary: This study found that nicotine-induced neuronal activity in the VTA is regulated by the LHb region, with acute and chronic nicotine having different effects on VTA DA neurons.

NEUROPHARMACOLOGY (2022)

Review Biochemistry & Molecular Biology

Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson's Disease

Abdeslam Chagraoui, Giuseppe Di Giovanni, Philippe De Deurwaerdere

Summary: The discovery of the D3 receptor has sparked interest in the field of neurological diseases, particularly Parkinson's disease. This article discusses the role of D3 receptors in Parkinson's disease and their relationship with current treatments, highlighting the potential interactions between D1 and D3 receptors that may contribute to motor side effects.

BIOMOLECULES (2022)

Article Biochemistry & Molecular Biology

Targeting the Ghrelin Receptor as a Novel Therapeutic Option for Epilepsy

An Buckinx, Dimitri De Bundel, Ron Kooijman, Ilse Smolders

Summary: Epilepsy is a neurological disease that affects over 50 million individuals worldwide. Despite the availability of various drugs for treatment, 30% of patients still suffer from pharmacoresistant epilepsy. Ghrelin receptor (ghrelin-R) has emerged as a promising new therapeutic target with anticonvulsant effects.

BIOMEDICINES (2022)

Article Biochemistry & Molecular Biology

Unraveling the Effects of GSK-3β Isoform Modulation against Limbic Seizures and in the 6 Hz Electrical Kindling Model for Epileptogenesis

Najat Aourz, Fred Van Leuven, Wissal Allaoui, Ann Van Eeckhaut, Dimitri De Bundel, Ilse Smolders

Summary: Two isoforms of glycogen synthase kinase-3 (GSK-3), GSK-3 alpha and GSK-3 beta, have been identified in mammals. This study investigates the role of GSK-3 beta in seizures and its potential as a drug target for pharmacoresistant seizures. The results suggest that GSK-3 beta inhibition has anticonvulsant effects, but sustained disruption of GSK-3 beta activity may contribute to kindling in the long term.

ACS CHEMICAL NEUROSCIENCE (2022)

Letter Neurosciences

The effect of cannabinoid receptor agonist WIN 55,212-2 on anxiety-like behavior and locomotion in a genetic model of absence seizures in the elevated plus-maze

Daniel Cassar, Manuela Radic, Maurizio Casarrubea, Vincenzo Crunelli, Giuseppe Di Giovanni

Summary: In this study, GAERS and NEC rats were treated with the CB1/2 receptor agonist WIN 55,212-2 (2 mg/kg) and tested on the Elevated Plus-Maze.

CNS NEUROSCIENCE & THERAPEUTICS (2022)

Review Pharmacology & Pharmacy

Current Approaches to Monitor Macromolecules Directly from the Cerebral Interstitial Fluid

Marie-Laure Custers, Liam Nestor, Dimitri De Bundel, Ann Van Eeckhaut, Ilse Smolders

Summary: This review discusses the applicability of microdialysis and other techniques for monitoring macromolecules in the brain, which is challenging due to the limited techniques available for direct sampling from the cerebral interstitial space. The review also addresses innovations, pitfalls, and research gaps in these techniques. Implementing these techniques can help improve drug development for brain-targeted drugs.

PHARMACEUTICS (2022)

Article Oncology

Targeting the β2-adrenergic receptor increases chemosensitivity in multiple myeloma by induction of apoptosis and modulating cancer cell metabolism

Hatice Satilmis, Emma Verheye, Philip Vlummens, Inge Oudaert, Niels Vandewalle, Rong Fan, Jennifer M. Knight, Nathan De Beule, Gamze Ates, Ann Massie, Jerome Moreaux, Anke Maes, Elke De Bruyne, Karin Vanderkerken, Eline Menu, Erica K. Sloan, Kim De Veirman

Summary: This study investigates the potential therapeutic effects of beta-blockers, specifically targeting the beta(2)-adrenergic receptor, in multiple myeloma treatment. The blockade of beta(2)-adrenergic receptors reduces cell viability, induces apoptosis and autophagy, and modulates cancer cell metabolism. Combining beta(2)AR blockade with other drugs enhances apoptosis in multiple myeloma cells.

JOURNAL OF PATHOLOGY (2023)

Article Clinical Neurology

Neurofilament light chain: A possible fluid biomarker in the intrahippocampal kainic acid mouse model for chronic epilepsy?

Marie-Laure Custers, Maxime Vande Vyver, Lea Kaltenbock, Kurt Barbe, Maria Bjerke, Ann Van Eeckhaut, Ilse Smolders

Summary: In the management of epilepsy, the discovery of new biomarkers is important for improving diagnosis, monitoring disease progression, and evaluating treatment responsiveness. This study investigates the potential of neurofilament light chain (NfL) as a diagnostic and response fluid biomarker for epilepsy.

EPILEPSIA (2023)

Review Neurosciences

Chemogenetic modulation of astrocytes and microglia: State-of-the-art and implications in neuroscience

Jo Bossuyt, Yana Van Den Herrewegen, Liam Nestor, An Buckinx, Dimitri De Bundel, Ilse Smolders

Summary: Insights into the roles of astrocytes and microglia in normal and diseased brain functioning have been greatly expanded in recent years, thanks to the emergence of chemogenetic tools. These cutting-edge techniques enable precise manipulation of specific glial cell types, leading to significant advances in our understanding of how glial cells contribute to various central nervous system functions and diseases. This article discusses the latest findings in glial cell functions using chemogenetics, focusing on the manipulation of intracellular signaling pathways in astrocytes and microglia induced by designer receptors exclusively activated by designer drugs (DREADDs). The potential limitations and translational prospects of this technology are also explored.
Article Oncology

Metformin confers sensitisation to syrosingopine in multiple myeloma cells by metabolic blockage and inhibition of protein synthesis

Arne Van der Vreken, Inge Oudaert, Gamze Ates, Sylvia Faict, Philip Vlummens, Hatice Satilmis, Rong Fan, Anke Maes, Ann Massie, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Eline Menu

Summary: This study suggests an alternative combination treatment for multiple myeloma by targeting metabolic pathways. The combination of syrosingopine and metformin shows strong cytotoxic effects on multiple myeloma cell lines and patient samples, suppressing both glycolysis and oxidative phosphorylation. Furthermore, the combination treatment leads to a significant reduction in tumor burden in vivo.

JOURNAL OF PATHOLOGY (2023)

Article Chemistry, Analytical

Improving the LC-MS/MS analysis of neuromedin U-8 and neuromedin S by minimizing their adsorption behavior and optimizing UHPLC and MS parameters

Jana Bongaerts, Dimitri De Bundel, Ilse Smolders, Debby Mangelings, Yvan Vander Heyden, Ann Van Eeckhaut

Summary: Neuromedin U (NmU) and neuromedin S (NmS) are neuropeptides belonging to the neuro-medin family. Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) is the preferred analytical technique for peptide quantification, but quantification limits for these peptides in biological samples remain challenging due to nonspecific binding. This study focuses on solving the adsorption problem and improving the sensitivity of the LC-MS/MS method for NmU and NmS.

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2023)

Article Biochemistry & Molecular Biology

Neuroanatomical characterization of the Nmu-Cre knock-in mice reveals an interconnected network of unique neuropeptidergic cells

Mireia Medrano, Wissal Allaoui, Mathias Van Bulck, Sofie Thys, Leila Makrini-Maleville, Eve Seuntjens, Winnok H. De Vos, Emmanuel Valjent, Balazs Gaszner, Ann Van Eeckhaut, Ilse Smolders, Dimitri De Bundel

Summary: Neuromedin U (NMU) is an evolutionarily conserved neuropeptide that plays a role in various processes. A knock-in mouse model expressing Cre recombinase under the Nmu promoter has been generated, allowing a comprehensive characterization of NMU-expressing neurons in the brain. The model has been validated using multiple approaches, and the results suggest that it is a powerful and sensitive tool for studying the role of NMU neurons in mice.

OPEN BIOLOGY (2023)

Article Neurosciences

A quantitative and T-pattern analysis of anxiety-like behavior in male GAERS, NEC, and Wistar rats bred under the same conditions, against a commercially available Wistar control group in the hole board and elevated plus maze tests

Maurizio Casarrubea, Manuela Radic, Tatiana Pinto Morais, Erika Mifsud, Eleonora Cuboni, Stefania Aiello, Giuseppe Crescimanno, Vincenzo Crunelli, Giuseppe Di Giovanni

Summary: The study compared Genetic Absence Epilepsy Rats from Strasbourg (GAERS), non-epileptic control (NEC), and Wistar rats bred under the same conditions, along with commercially available Wistar rats (Cm Wistar) as a control. The results showed that male GAERS rats lacked comorbid anxiety, and the study emphasized the importance of using Wistar rats from the same breeding conditions.

CNS NEUROSCIENCE & THERAPEUTICS (2023)

Article Geriatrics & Gerontology

The intracerebral injection of Aβ1-42 oligomers does not invariably alter seizure susceptibility in mice

Maxime Vande Vyver, Louise Daeninck, Gino De Smet, Najat Aourz, Surajit Sahu, Sebastiaan Engelborghs, Kris Pauwels, Dimitri De Bundel, Ilse Smolders

Summary: We investigated the impact of A beta(1-42) oligomers on seizure susceptibility in mice and found no effect after intracerebral injection. Despite confirming the presence of A beta(1-42) oligomers, it remains unclear whether our findings or previous studies best represent the role of these oligomers in seizures in AD.

FRONTIERS IN AGING NEUROSCIENCE (2023)

Article Oncology

Targeting S100A9 protein affects mTOR-ER stress signaling and increases venetoclax sensitivity in Acute Myeloid Leukemia

Rong Fan, Hatice Satilmis, Niels Vandewalle, Emma Verheye, Elke De Bruyne, Eline Menu, Nathan De Beule, Ann De Becker, Gamze Ates, Ann Massie, Tessa Kerre, Marie Torngren, Helena Eriksson, Karin Vanderkerken, Karine Breckpot, Ken Maes, Kim De Veirman

Summary: This study identifies S100A9 as a novel molecular target for treating AML. Targeting S100A9 can reduce the viability and proliferation of AML cells by inhibiting mTOR and endoplasmic reticulum stress signaling, and increase the sensitivity of AML cells to venetoclax. The clinically available S100A9 inhibitor tasquinimod also has similar therapeutic effects. These findings are of great importance for the treatment of AML.

BLOOD CANCER JOURNAL (2023)

暂无数据